Cambridge Cognition Holdings plc (LON:COG), the digital neuroscience company which develops and markets digital solutions to assess brain health, has today announced a new strategic collaboration and partnership with the University of Bristol to accelerate the development of novel brain health products.
Mental and substance use disorders are now the leading cause of disability worldwide, resulting in 23% of all years lost with a global economic loss of a trillion US dollars every year1.
New scalable tools are needed to measure mental health objectively and to enable clinicians to better diagnose and monitor patients.
Cambridge Cognition’s digital health products exemplify how new technologies can transform clinical research and health, while the team at the University of Bristol, led by Professor Marcus Munafò, brings expertise in mental health and addiction along with an established network of patient groups and clinicians.
The creation of this collaboration will enable the Company to run in-patient studies with the University and accelerate the development of new software applications to help clinicians address the global need in mental health conditions.
Professor Marcus Munafò, Professor of Biological Psychology, University of Bristol said: “This is an exciting opportunity to rapidly translate our research into clinical practice and patient benefit. We have worked with Cambridge Cognition for several years and this partnership allows us to extend this work and build on their experience of digital neuroscience.”
Dr Jenny Barnett, Chief Scientific Officer, Cambridge Cognition Holdings plcn said: “We are delighted to extend and formalise our relationship with the talented team at the University of Bristol. Working more closely will enable us to build a pipeline of novel, evidence-based and usable tools to better measure and monitor mental health across all ages groups and accelerate our ability to validate our digital health apps in a clinical setting.”
